Victory Pharma
Leveraging science-based heritage to develop and commercialize pharmaceutical products to treat unmet medical needs in the areas of infectious diseases and pain.
Launch date
Employees
Market cap
€12.5b
Enterprise valuation
€8.6b (Public information from Sep 2024)
Share price
JPY6464 4507.T
Florham Park New Jersey (HQ)
Notable known LPs: Shionogi
Financials
Estimates*
JPY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 333.4b | 297.2b | 335.1b | 426.7b | 435.1b | 55.4b | 57.8b |
% growth | - | (11 %) | 13 % | 27 % | 2 % | (87 %) | 4 % |
EBITDA | 175.2b | 158.7b | 143.5b | 242.0b | 223.3b | - | - |
% EBITDA margin | 53 % | 53 % | 43 % | 57 % | 51 % | - | - |
Profit | 122.2b | 111.9b | 114.2b | 185.0b | 162.0b | - | - |
% profit margin | 37 % | 38 % | 34 % | 43 % | 37 % | - | - |
R&D budget | 47.9b | 54.2b | 73.0b | 102.4b | 102.6b | - | - |
R&D % of revenue | 14 % | 18 % | 22 % | 24 % | 24 % | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
* | $118m | Acquisition | |
$7.6m | Grant | ||
Total Funding | €6.9m |
Recent News about Victory Pharma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.